Rituximab Monoclonal Antibody from Japan
Rituximab is a genetically engineered chimeric monoclonal antibody targeting CD20 on B-cells, used to treat non-Hodgkin lymphoma and rheumatoid arthritis. Imported in bulk, unmixed form without retail packaging, it falls under tariff item 3002.13.00.
Duty Rate — Japan → Canada
0%
Import Tips
• Maintain records showing the product is a single, unmixed substance to support the classification
• Ensure no retail packaging or dosing instructions are included in the shipment
• Check if a Clinical Trial Application or Drug Submission is needed for the intended use